Abstract | BACKGROUND: METHODS: RESULTS: Six out of seven TNBC cell lines demonstrated a synergistic interaction using the triple- drug combination, compared with only two TNBC cell lines with the cisplatin and cetuximab combination. An induction of apoptosis and decrease in EGFR and mitogen-activated protein kinase phosphorylation, and thus resensitization to EGFR inhibition, was observed using the three- drug treatment regimen. A significant reduction (P < 0.001) in tumor cell migration and invasion was also found following dasatinib treatment alone or in combination. CONCLUSIONS: These findings may have important clinical implications in treating TNBC patients whose tumors co-overexpress both EGFR and c-Src. Identification of this subset of patients may be beneficial in the design of a clinical trial using this treatment regimen.
|
Authors | Elizabeth M H Kim, Kelly Mueller, Elaina Gartner, Julie Boerner |
Journal | The Journal of surgical research
(J Surg Res)
Vol. 185
Issue 1
Pg. 231-9
(Nov 2013)
ISSN: 1095-8673 [Electronic] United States |
PMID | 23899511
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Published by Elsevier Inc. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Pyrimidines
- Thiazoles
- EGFR protein, human
- ErbB Receptors
- Cetuximab
- Cisplatin
- Dasatinib
|
Topics |
- Antibodies, Monoclonal, Humanized
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Apoptosis
(drug effects)
- Cell Line, Tumor
- Cell Movement
(drug effects)
- Cetuximab
- Cisplatin
(pharmacology)
- Dasatinib
- Drug Resistance, Neoplasm
- Drug Synergism
- ErbB Receptors
(antagonists & inhibitors)
- Female
- Humans
- Neoplasm Invasiveness
(pathology)
- Protein Kinase Inhibitors
(pharmacology)
- Pyrimidines
(pharmacology)
- Thiazoles
(pharmacology)
- Triple Negative Breast Neoplasms
(drug therapy, pathology)
|